Portfólio


ARTIGOS

Mortes preveníveis: Como pode alguém morrer de asma em pleno século XXI?

Em estudo, mais da metade das mortes foram de pacientes com asma leve ou moderada, e especialistas concluíram que provavelmente nem os pacientes nem os médicos reconheceram a gravidade da doença. .

HIV: A um passo da cura?

Estudo brasileiro para a erradicação do HIV e da aids apresenta aumento da resposta das células T CD8+, levando dois pacientes a negativar o DNA do vírus nas células .

PrEP no SUS: orientações aos médicos

Entenda o que é a profilaxia pré-exposição, suas indicações e para onde encaminhar os pacientes.

Clinical Trial Lancet Infect Dis. 2014 Jun;14(6):459-67. doi: 10.1016/S1473-3099(14)70711-X. Epub 2014 Apr 9


Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): A multicentre, phase 2, non-comparative, open-label, randomised trial


Concurrent treatment of HIV and tuberculosis is complicated by drug interactions. We explored the safety and efficacy of raltegravir as an alternative to efavirenz for patients co-infected with HIV and tuberculosis.

0264-410X © 2012 Elsevier Ltd. https://dx.doi.org/10.1016/j.vaccine.2012.12.023 Open access under the Elsevier OA license. Open access under the Elsevier OA license. 


Higher cross-subtype IFN- ELISpot responses to Gag and Nef peptides in Brazilian HIV-1 subtype B- and F1- than in C-infected subjects


HIV-1 diversity has been considered a huge challenge for the HIV-1 vaccine development. To overcome it, immunogens based on centralized sequences, as consensus, have been tested. In Brazil,the co-circulation of three subtypes offers a suitable scenario to test T cell cross-subtype responses to consensus sequences. Furthermore, we included peptides based on closest viral isolates (CVI) from each subtype analyzed to compare with T cell responses detected against the consensus sequences.

Retrovirology. 2012; 9(Suppl 2): P150.Published online 2012 Sep 13. doi: 10.1186/1742-4690-9-S2-P150


HIV-1 subtype B- and F1-infected subjects display higher cross-clade T-Cell response than subtype C-infected subjects


The impact of the extensive genetic diversity of the HIV-1 group M isolates and its implications for vaccine design have long been discussed. Studies indicate that Gag and Nef conserved epitopes are commonly recognized and give rise to high cross-clade responses. The aim of this study was to compare T-cell responses to peptide pools derivate from subtype B, C and F1 consensus, among Brazilian subjects infected with those three HIV-1 subtypes.

Rev. Inst. Med. Trop. Sao Paulo 53(3):173-175, May-June, 2011 doi: 10.1590/S0036-46652011000300010 


CASE REPORT: CMV AND HSV-2 MYELORADICULITIS IN AN HIV INFECTED PATIENT 


While CMV myeloradiculitis is a known complication in AIDS patients with severe immunosuppression, HSV-2 necrotizing myeloradiculitis is rare and often associated with disabling a fatal outcome. We hereby describe a 46 year-old HIV infected patient with profound and sustained immunosuppression who presented with an acute ascending paraparesis and urinary retention. Lumbar spine MRI showed contrast enhancement at the conus medullaris and cauda equine, and both CMV and HSV-2 CSF PCR were positive. Despite treatment, the patient died 20 days later. We review the main diagnostic and therapeutic aspects of herpes virus associated myeloradiculitis and discuss the approach in similar cases.

HIV Medicine (2008), 9, 883-896
DOI: 10.1111/j.1468-1293.2008.00644.x


Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor‐naïve, nonnucleoside reverse transcriptase inhibitor‐experienced patients: study TMC125‐C227†

TMC125‐C227, an exploratory phase II, randomized, controlled, open‐label trial, compared the efficacy and safety of TMC125 (etravirine) with an investigator‐selected protease inhibitor (PI) in nonnucleoside reverse transcriptase inhibitor (NNRTI)‐resistant, protease inhibitor‐naïve, HIV‐1‐infected patients.

Tratamento clínico da infecção pelo HIV - 2004

Dr. John G. Bartlett e Dr. Joel Gallant

Johns Hopkins University

Tradução: Carla Vorsatz
Revisão técnica: Dra. Jacqueline A. Menezes

Tratamento clínico da infecção pelo HIV - 2005-2006

Dr. John G. Bartlett e Dr. Joel Gallant

Johns Hopkins University

Tradução: Carla Vorsatz
Revisão técnica: Dra. Jacqueline A. Menezes 



Bioestatística Básica e Clínica

3a edição - 2003 | McGraw-Hill

Revisão de Conteúdo: Héctor Gustavo Arango

Tradução
Carla de Mello Vorsatz

Carlos Henrique de Araújo Cosendey

Marco Antonio Valejo

As Bases Farmacológicas da Terapêutica - 10a edição 2003 McGraw-Hill

Revisão: Almir Lourenço da Fonseca

Tradução
Carla de Mello Vorsatz

Carlos Henrique Cosendey

Denise Costa Rodrigues

Marco Antonio Valejo
Patricia Lydie Voeux

CARDIOLOGIA: DIAGNÓSTICO E TRATAMENTO - 2a edição 2004

McGraw-Hill

Michael H. Crawford 


Tradução Carla Vorsatz e outros

Harrison Medicina Interna 15a edição - 2002
McGraw-Hill


Tradução Carla Vorsatz e outros 

ORTOPEDIA: DIAGNÓSTICO E TRATAMENTO - 3a edição 2005

McGraw-Hill 
Harry Skinner

Tradução: Carla Vorsatz e outros

Harrison Manual de Medicina Interna - 15a edição

McGraw-Hill

Tradução Carla Vorsatz e outros